000			01906 a2200493 4500
005			20250516145709.0
264		0	_c20140826
008			201408s 0 0 eng d
022			_a1872-6054
024	7		_a10.1016/j.healthpol.2013.03.006 _2doi
040			_aNLM _beng _cNLM
100	1		_aSandmann, Frank G
245	0	0	_aDo reassessments reduce the uncertainty of decision making? Reviewing reimbursement reports and economic evaluations of three expensive drugs over time. _h[electronic resource]
260			_bHealth policy (Amsterdam, Netherlands) _cOct 2013
300			_a285-96 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAdalimumab
650	0	4	_aAnti-Inflammatory Agents _xeconomics
650	0	4	_aAntibodies, Monoclonal, Humanized _xeconomics
650	0	4	_aAntineoplastic Agents _xeconomics
650	0	4	_aBenzamides _xeconomics
650	0	4	_aDecision Making
650	0	4	_aDrug Costs _xstatistics & numerical data
650	0	4	_aEconomics, Pharmaceutical
650	0	4	_aEvidence-Based Practice
650	0	4	_aFilgrastim
650	0	4	_aGranulocyte Colony-Stimulating Factor _xeconomics
650	0	4	_aHealth Expenditures _xstatistics & numerical data
650	0	4	_aHumans
650	0	4	_aImatinib Mesylate
650	0	4	_aInsurance, Health, Reimbursement _xeconomics
650	0	4	_aNetherlands
650	0	4	_aPiperazines _xeconomics
650	0	4	_aPolyethylene Glycols
650	0	4	_aPyrimidines _xeconomics
650	0	4	_aRecombinant Proteins _xeconomics
650	0	4	_aReimbursement Mechanisms
650	0	4	_aUncertainty
700	1		_aFranken, Margreet G
700	1		_aSteenhoek, Adri
700	1		_aKoopmanschap, Marc A
773	0		_tHealth policy (Amsterdam, Netherlands) _gvol. 112 _gno. 3 _gp. 285-96
856	4	0	_uhttps://doi.org/10.1016/j.healthpol.2013.03.006 _zAvailable from publisher's website
999			_c22709780 _d22709780